• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering extends use of Gadovist

Article

The European Union has approved the use of Schering's extracellular agent Gadovist 1.0 for use in MR angiography. Gadovist 1.0 previously had been cleared for contrast-enhanced MR of the brain and spine by EU members and other countries, including the

The European Union has approved the use of Schering's extracellular agent Gadovist 1.0 for use in MR angiography. Gadovist 1.0 previously had been cleared for contrast-enhanced MR of the brain and spine by EU members and other countries, including the U.S. It is the first extracellular contrast agent to receive EU approval for this indication.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.